The Florida Society of Nephrology would like to express our heartfelt gratitude to all the sponsors and exhibitors who generously support the FSN 58th Annual Meeting.
Attendees will have the opportunity to learn more about these organizations and meet their representatives at the meeting.
Diamond Partner
|
|
|
|
Otsuka
Recognizing a critical gap in clinical expertise and research within nephrology, Otsuka took the initiative to pioneer advancements. Otsuka’s commitment remains steadfast in developing groundbreaking therapeutics in nephrology and
other areas. Through enduring perseverance, Otsuka remains focused on offering renewed hope to patients and clinicians.
|
|
 |
| |
|
|
Platinum Partners
|
|
|
| Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish
the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. |
|
 |
| |
|
|
| At Travere Therapeutics we are in rare for life. We come together every day to help patients, families and caregivers as they navigate life with a rare
disease. On this path, we know the need for treatment options is urgent and we work with the rare disease community to identify, develop and deliver life-changing therapies. We continuously seek to understand the diverse perspectives
of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. |
|
 |
| |
|
|
Gold Partner
|
|
|
| Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the
biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. |
|
|
| |
|
|
| Aurinia Pharmaceuticals is a commercial stage biopharmaceutical
company focused on developing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company received FDA approval for their first commercially available drug product
in January 2021. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally. Please visit www.AuriniaLN.com
to learn more about our product. |
|
 |
| |
|
|
Silver Partner
|
|
|
Alnylam Pharmaceuticals Since its founding, Alnylam has led the translation of RNA interference (RNAi) into a new class of approved and investigational medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Alnylam is headquartered in Cambridge, MA. For more information, visit www.alnylam.com. | |  | | | | |
| Mallinckrodt Pharmaceuticals is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. |
|
 |
| |
|
|
Novartis is reimagining medicine to improve and extend people’s lives.
We deliver high-value medicines that alleviate society’s greatest disease burdens through
technology leadership in R&D and novel access approaches.
We consistently rank among the world’s top companies investing in research and development.
Novartis employs about 14,000 people in the United States.
|
|
 |
| |
|
|
| Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments
that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks
both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN). In addition to IgAN, Vera is evaluating additional diseases where the reduction of
autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BKV, a polyomavirus that can have devastating consequences in certain settings such
as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. |
|
 |
| |
|
|
Bronze Partners
|
|
|
| ANI Pharmaceuticals |
|
 |
| |
|
|
| Alexion - AstraZeneca Rare Disease |
|
 |
| |
|
|
| Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people
by supporting efforts to overcome the major challenges presented by a growing aging population. Bayer is committed to the principles of sustaining development, and the Bayer brand stands for trust, reliability, and quality throughout
the world. |
|
 |
| |
|
|
Calliditas Therapeutics is dedicated to expanding treatment options and establishing new standards of care for people with rare diseases. By drawing on our expertise in pharmaceutical product development and leveraging our strategic partnerships, we quickly and efficiently identify, develop, and market a pipeline of innovative medicines that can improve the lives of patients. |
|
 |
| |
|
|
| CareDX is committed to improving transplant patient outcomes by providing innovative and intelligent solutions throughout the entire patient journey. We are a leading
precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients. |
|
 |
| |
|
|
| Central Florida Kidney Centers |
|
 |
| |
|
|
| CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. |
|
 |
| |
|
|
|
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and
nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier
lives.
|
|
 |
| |
|
|
Eurofins Transplant Genomics Meeting the needs of transplant patients and providers is a challenge unlike another. From pre- to post-transplant, we’re equipped with
testing solutions that can do just that. Eurofins Transplant Genomics and Eurofins Ascend come together to provide testing solutions for all stages of the transplant journey.
|
|
 |
| |
|
|
|
Fresenius Medical Care North America. With comprehensive solutions for people living with chronic kidney disease and related conditions, we are working together to improve
the quality of life of every patient, every day. We are transforming healthcare through research, innovation, and compassion.
|
|
 |
| |
|
|
| MedPro Group & Risk-Strategies |
|
 |
| |
|
|
| |
|
|
Natera is a global leader in cfDNA testing. Developed by our trusted legacy in cfDNA, the Prospera transplant assessment test is optimized to be a precise and
reliable tool for early, clinically-meaningful rejection assessment. Renasight, a renal genetics panel, is a comprehensive, accessible genetic test for patients with CKD.
|
|
 |
| |
|
|
| OPKO Renal Developing novel therapies to treat secondary hyperparathyroidism associated with chronic kidney disease. The Renal Division of OPKO Health, Inc.
focuses on developing proprietary products to treat secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). We are proud of our lead nephrology product, Rayaldee® (calcifediol), launched in 2016. In addition,
the Renal Division is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients. OPKO’s expertise in Vitamin D chemistry, biochemistry, metabolism
and physiology, combined with its experience in successfully bringing Vitamin D therapeutics to market uniquely positions the Renal Division to improve the lives of CKD patients. |
|
 |
|
Quanta Dialysis Technologies is committed to making high-quality and cost-effective dialysis accessible to every patient in every setting with its Quanta
Dialysis System - the first and only FDA-cleared device to perform IHD, SLED, and CRRT (CVVHD and SCUF) without any need for bags.
|
|
 |
EXHIBITORS
|
|
|
Akebia | | | Alnylam Pharmaceuticals | | | | | | |
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the
most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3.
|
|
 |
| |
|
|
| Ardelyx is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical
needs. |
|
 |
| |
|
|
Arkana Laboratories is a center for esoteric pathology specializing in renal pathology, neuropathology, and contract research. It is our mission to improve patient
care by advancing understanding of disease and providing world-class diagnostics. We are committed to providing doctors with the highest quality, clinicopathologic discussion possible. We recognize that in order to best serve
the needs of our clinicians we must work together with them, not just as a lab, but as an extension of their practice. It is our goal to help equip doctors with the results they need to deliver the most effective patient care possible.
As pathologists, we recognize that the longest period in a patient’s life is the timeframe between the day he/she has a biopsy, and the day the result arrives.
|
|
 |
| | | | AstraZeneca LP | | | | | | | Azura Vascular Care | | |
Baxter Vantive will build on Baxter’s nearly 70-year commitment to pioneering therapies for kidney patients and providers across modalities. Products will include peritoneal dialysis devices and solutions; connected technologies like the Sharesource remote patient management system; organ support therapies including continuous renal replacement therapy; and hemodialysis filters and systems. |
|
 |
| | | | Chiesi Global Rare Diseases | | | | | | | DaVita | | | | | | |
Empower Healthcare & Compliance Partners |
|
|
| |
|
|
Fresenius Kidney Care is dedicated to achieving optimal sustainable clinical, quality and technological standards in patient care by providing high-quality, personalized
care, resources, and support.
We help people with the physical and emotional challenges of kidney disease so they can lead meaningful and fulfilling lives on their own terms.
|
|
 |
| |
|
|
| GSK unites science, technology and talent to get ahead of disease together. We prevent and treat disease with vaccines, specialty and general medicines. |
|
 |
| | | |
HCA Florida Largo Hospital |
|
|
| | | |
| Healthmap Solutions is a kidney population health management company with a mission to improve care and lower costs for people living with kidney disease. Healthmap
uses advanced technology, predictive analytics, and clinical expertise to slow disease progression and deliver personalized, whole-person care management. |
|
 |
| |
|
|
InBody BWA’s sole mission is to improve lives through improved standard of care for the critically ill. Guided by our body water analysis, clinicians and researchers
will be bringing more precision to patient care. We are the only bioelectrical impedance analysis (BIA) device validated at 98% to DEXA by Mayo Clinic and are used in nearly 7,000 peer-reviewed studies worldwide. Beyond the device,
we continue to update our database with the latest research across many disciplines, which has helped us connect researchers who go on to collaborate and share data to further expand their field. Find out more at inbodybwa.com
|
|
 |
Kyowa Kirin |
|
|
The Miami Transplant Institute (MTI) is a distinguished collaboration between the University of Miami Miller School of Medicine and Jackson Memorial Hospital. For over half a century, MTI has successfully performed nearly 10,000 kidney transplants, showcasing a long-standing legacy of excellence. MTI is one of the largest kidney transplant programs in Florida and stands as a national leader in providing life-saving kidney and pancreas transplant surgeries using robotic laparoscopic technology. Our expertise extends to highly complex and challenging transplant cases, and we are proud of our exceptional post-transplant outcomes.
|
|
 |
| |
|
|
National Dialysis Accreditation Commission is the leading dialysis Accreditation Organization (AO) in the U.S. and was the first AO approved by CMS for deemed
status for ESRD. Dialysis providers successfully completing NDAC’s accreditation process may be awarded Medicare certification from CMS. NDAC provides accreditation in all 50 states and U.S. territories.
Learn more about
us at www.ndacommission.com or contact us today at info@ndacommission.com.
|
|
 |
| | | |
The National Kidney Foundation of Florida provides lifesaving education and services for patients and families affected by kidney disease through advocacy, innovation, and support. At the National Kidney Foundation (NKFF) over 84 cents out of every dollar is used for patient programs. NKFF’s strong financial health and commitment to accountability and transparency have earned it a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. The NKFF’s exceptional 4-star rating sets it apart from its peers and demonstrates its trustworthiness to the public.
| |  |
Nephro-Tech, Inc
|
|
|
| Neway is the U.S. leader in value-based care for dialysis labs. We help dialysis programs achieve better financial outcomes while increasing the quality and velocity
of patient care. Neway with Quest Diagnostics® delivers next-day lab results, and the Neway Lab Stewardship Program® helps lower your lab costs. |
|
 |
| |
|
|
| Novo Nordisk is a global healthcare company committed to discovering and developing innovative medicines to help people with serious chronic conditions and rare
diseases lead longer, healthier lives. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure life-threatening diseases. |
|
 |
| |
|
|
| Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System,
FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. |
|
 |
| | | |
Pentec Health |
|
|
| | | |
Physician Software Systems – technology to meet the challenges dialysis providers are facing in 2025!
Providing AI-driven, individualized, ESA and iron dosing decision
support to improve patient care, automation to streamline clinical tasks and improve efficiency, and operational oversight and assistance from senior team members to staff at individual units.
|
|
 |
| |
|
|
Renalytix - Our singular goal is to eradicate kidney disease. With our KidneyIntelX™ technology, we help clinical teams understand patient level of risk for progressive
decline in kidney function in the earliest stages of diabetic kidney disease. Knowing patient risk early enables clinicians to focus resources and guideline-recommended treatment accordingly, which provides the best chance for
improving outcomes.
|
|
 |
Takeda | | |
| |
|
|
| Tampa General Hospital Transplant Institute A national leader in transplant surgery for 50 years, Tampa General Hospital Transplant
Institute has performed more than 7,700 kidney transplants. Ranked in the top 10 in the nation by volume, the TGH Transplant Institute brings together a world-class team of specialists to offer individualized care for patients. |
|
 |
| |
|
|
UF Health Transplant Center: Our commitment is reflected in outstanding outcomes. SRTR data released in January 2024, placed UF Health No. 2 nationally among kidney transplant
programs for the third reporting period in a row and No. 1 in Florida for speed to transplant and 1-year kidney survival.
|
|
 |
| |
|
|
University of Florida Health Pathology Laboratories is the largest academic outreach pathology laboratory in Florida, offering comprehensive pathology services to hospitals and physician groups throughout the state.
To learn more, visit us online at: pathlabs.ufl.edu.
|
|
 |
| |
|
|
| |
|
|
|
Florida Women in Nephrology Chair
FSN President
Print Page